<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00212888</url>
  </required_header>
  <id_info>
    <org_study_id>2000456-01H</org_study_id>
    <secondary_id>CTA file 9427-C1574-32C</secondary_id>
    <nct_id>NCT00212888</nct_id>
  </id_info>
  <brief_title>Combination Vaccination Before HIV Treatment Interruption</brief_title>
  <official_title>A Pilot Study to Determine the Impact of Therapeutic HIV Vaccination Followed by a Scheduled Interruption of Antiretroviral Therapy on HIV-Specific Immune Function and Virologic Rebound in Patients With Prolonged Viral Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ontario HIV Treatment Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CIHR Canadian HIV Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if vaccination before a structured treatment
      interruption (STI) is associated with an improvement in immune function, resulting in a
      delayed and reduced rebound in the amount of HIV virus in the blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volunteers will be randomly assigned to receive the vaccines or matching placebos before
      interrupting their antiretroviral therapy at week 24.

      Dosage:

      Remune(TM) 1 ml i.m.* at weeks 0, 12, and 20; ALVAC 1 ml i.m.* at weeks 8,12, 16, and 20.

      * i.m.: injected in a muscle
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to detectable virus in the Remune plus ALVAC group and the placebo group (between group t-test)</measure>
    <time_frame>ongoing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to detectable virus in the ALVAC alone group and the placebo group</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rebound of plasma HIV RNA level to 10,000 copies/ml</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral set-point</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of viral rebound</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-specific immune function</measure>
    <time_frame>at week 48</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Remune and ALVAC</intervention_name>
    <description>Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);
Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or
Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV infection (by serology)

          -  HIV RNA level below 50 copies/ml for at least two years

          -  Receiving at least 2 antiretroviral agents including at least 1 protease inhibitor or
             1 non-nucleoside reverse transcriptase inhibitor at time of screening

          -  Have CD4 counts above 500 cells/ul

          -  Have CD4/CD8 ratio above 0.5

          -  Have never had a CD4 count below 250

          -  No previous AIDS-defining opportunistic infection

          -  No previous cancer chemotherapy or other system immunosuppressive therapy (excluding
             brief courses [&lt;= 1 month] of prednisone or its equivalent)

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Hepatitis B surface antigen positive

          -  Hepatitis C antibody positive

          -  AST, ALT, ALP, creatinine, urea above three times the normal upper limit

          -  Blood abnormalities (hemoglobin lower than 100, white blood cell count [WBC] lower
             than 1500 or platelets lower than 100)

          -  Allergies to components of Remune™ or ALVAC

          -  Contraindications to vaccine components

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan B Angel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHRI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital, General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hotel-Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 28, 2017</submitted>
    <returned>June 14, 2017</returned>
    <submitted>July 5, 2017</submitted>
    <returned>January 29, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

